-+ 0.00%
-+ 0.00%
-+ 0.00%

Biofrontera Q3 net loss narrows to $6.42 million; Q3 net product revenue rises 30% to $9.07 million

PUBT·11/13/2026 13:04:35
Listen to the news
Biofrontera Q3 net loss narrows to $6.42 million; Q3 net product revenue rises 30% to $9.07 million
  • Biofrontera’s third-quarter 2026 net loss narrowed to $6.42 million.
  • Net product revenue climbed 30% year over year to $9.07 million, primarily driven by higher Ameluz unit volume.
  • Gross margin rose to 74.4% from 70.7% a year earlier, principally due to lower Ameluz costs following the strategic transaction.
  • Ameluz secured FDA approval for superficial basal cell carcinoma; commercialization is planned for late fourth-quarter 2026 into first-quarter 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biofrontera Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611130802PRIMZONEFULLFEED9877171) on November 13, 2026, and is solely responsible for the information contained therein.